H epatocellular carcinoma (HCC) is the only malignancy that can be diagnosed based on imaging characteristics without the need for histology, largely due to its unique vascular pattern (arterial hyperenhancement followed by washout).
H epatocellular carcinoma (HCC) is the only malignancy that can be diagnosed based on imaging characteristics without the need for histology, largely due to its unique vascular pattern (arterial hyperenhancement followed by washout). (1) Therefore, it is important to establish well-defined imaging criteria for HCC diagnosis that provide high sensitivity while maintaining high specificity. (2) Abbreviations: AASLD Despite the evolution of HCC diagnostic criteria based on an accumulation of clinical experiences and advances in imaging technology, the HCC criteria proposed by Western guidelines such as those of the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL) are hampered by low sensitivity because nonnegligible portions of HCC, particularly small HCC, do not meet these criteria based on vascular profiles. (1, 3, 4) In 2008, a committee of radiologists from the American College of Radiology developed the Liver Imaging-Reporting and Data System (LI-RADS) to standardize interpretation, reporting, and the collection of imaging data in patients at risk for developing HCC. (5, 6) The goal of LI-RADS is to increase the consistency of categorizing liver lesions while maintaining high specificity for HCC diagnosis, (7) which is congruent with the AASLD and the Organ Procurement and Transplantation Network/United Network for Organ Sharing (OPTN/UNOS) systems. (1, 8) Additionally, LI-RADS can potentially increase the diagnostic accuracy for HCC by incorporating ancillary features. (5, 9) Gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid (Gd-EOB-DTPA or gadoxetic acid disodium) is a liver-specific magnetic resonance contrast agent that has the combined properties of an extracellular contrast agent (ECA) and a hepatobiliary agent (HBA). (10) (11) (12) The strength of this agent is that it delineates most liver lesions as areas of hypointense defects against strongly enhanced adjacent liver parenchyma on the hepatobiliary phase (HBP) image. (13) This leads to improved sensitivity for HCC diagnosis as well as additional tumor detection. (14) However, when applying hypointensity on the transitional phase (TP) or HBP of magnetic resonance imaging (MRI) with HBA (HBA-MRI), erroneous diagnosis of non-HCC hypervascular tumors is a major concern as gadoxetic acid begins to be taken up by hepatocytes approximately 60-90 seconds after contrast injection. (15, 16) Thus, in LI-RADS, washout appearance on HBA-MRI is assessed only in the portal venous phase (PVP) prior to the TP or HBP. Therefore, hypointensity on TP or HBP is not considered to be an alternative to washout of ECA-MRI but is an ancillary feature. (5) Although a few studies have compared computed tomography with either conventional dynamic ECA-MRI or HBA-MRI, (7, 17) no studies have compared ECA-MRI and HBA-MRI with regard to diagnostic performance based on LI-RADS for HCC diagnosis. Thus, the goal of this prospective study was to compare the efficacy of HBA-MRI and ECA-MRI in the diagnosis of HCC with LI-RADS v2017 in an intraindividual, crossover manner.
Materials and Methods

patieNtS
This prospective study was approved by our institutional review board and followed the Declaration of Helsinki and subsequent amendments. Written informed consent was obtained from each patient before enrollment in the study. Between November 2016 and November 2017, we recruited adults (18 years old) with chronic hepatitis or cirrhosis who had been referred to an academic referral institution due aRtiCle iNFoRMatioN:
to a suspected hepatic tumor on ultrasound (US) and were scheduled to undergo liver surgery. The inclusion criteria for this crossover intraindividual comparison of the two MRIs were (1) newly diagnosed hepatic nodule of 3 cm in diameter on MRI, (2) no history of HCC treatment before the MRI examination, and (3) two MRIs performed within a 30-day interval (median, 15 days; range, 9-30 days). When the patient decided to undergo liver surgery, a second MRI was performed. Because our institutional policy is that HBA is preferred over ECA as a magnetic resonance contrast agent for patients suspected of having HCC, most patients had undergone HBA-MRI as the first magnetic resonance examination, followed by ECA-MRI. We excluded patients with hepatic tumors >3 cm, patients who had received treatment for HCC, patients who had a history of allergic reaction after the administration of a contrast agent, those who had refused consent, those who had a longer than 1-month time interval between the two MRIs, and those who had inadequate quality of MRI. We finally enrolled 91 patients (76 men, 15 women; age range, 32-76 years) (Fig. 1) . Clinicopathologic characteristics of patients and observations are shown in Table 1 .
ReFeReNCe StaNDaRD
Reference standards for diagnosis of hepatic observations were based on histopathological examination of surgical specimens, except for three incidentally detected hemangiomas and 10 arterioportal (AP) shunts that were based on typical imaging findings and stability. Operations included segmentectomy (n = 36), sectionectomy (n = 16), lobectomy (n = 20), and wedge resection (n = 19). For HCC, the histopathological factors assessed for each tumor were gross type; nuclear grade; histological type; cell type; fibrous capsule and septum formation; vascular invasion; bile duct invasion; presence of fat, necrosis, or hemorrhage; presence of satellite nodule; and multicentric occurrence. Based on the nuclear grading scheme proposed by Edmondson and Steiner, (18) HCC tumor grade was categorized as I, II, III, or IV using a basic hematoxylin and eosin staining technique.
MRi eXaMiNatioN
MRI was acquired using a 3.0-T system (Intera Achieva 3.0-T; Philips Healthcare, Best, The Netherlands) equipped with a dual-source parallel radiofrequency transmission system and quadrature body coil. Baseline MRI included a T1-weighted turbo field-echo in-phase and opposed sequence, with breath-hold multishot T2-weighted imaging and respiratory-triggered heavily T2-weighted imaging. Diffusion-weighted imaging was acquired using respiratory-triggered single-shot echo planar imaging with b values of 0, 100, and 800 seconds/mm 2 . For contrast-enhanced imaging, unenhanced, arterial phase (25-30 seconds), portal phase (60 seconds), 3-minute delayed phase (TP in HBA-MRI), and 20-minute HBP images (only after HBA administration) were obtained using a T1-weighted three-dimensional turbo field-echo sequence (T1 high-resolution isotropic volume examination; Philips Healthcare). The time for arterial phase imaging was determined using the MR fluoroscopic bolus detection technique. Contrast agent was administered intravenously using a power injector at a rate of 1 mL/second for a dose of 0.025 mmol/kg body weight (Gd-EOB-DTPA, Primovist [Eovist in the United States]; Bayer HealthCare, Berlin, Germany) or at a rate of 2 mL/second for a dose of 0.1 mmol/kg body weight (Gd-DOTA, Dotarem, gadoterate meglumine; Guerbet, Aulnay-sous-Bois, France), followed by a 20-mL saline flush. Detailed parameters of magnetic resonance sequences used are summarized in Supporting Table S1 .
iMage aNalySiS
All MRI features were evaluated by two abdominal radiologists (with 12 and 11 years of experience in interpreting liver MRI) who were blinded to the final pathological diagnoses. All MRIs were retrieved from a picture archiving and communication system (Centricity Radiology RA 1000; GE Healthcare, Chicago, IL) and then deidentified by an investigator who did not participate in image analysis. The deidentified images were presented in a random order to the reviewers. To avoid bias, the two MRIs were analyzed in an anonymized and randomized manner. In order to minimize any learning bias, there was a 4-week interval between the blinded interpretations. Before the beginning of the study, both observers were given 3 months of hands-on instruction to practice using LI-RADS v2017 to explain liver lesions. The training cases were not included in this study group.
All assessed MRI features and their definitions on either ECA-MRI or HBA-MRI are shown in Supporting Table S2 . While assigning the LI-RADS score for each observation, observers independently Abbreviation: AFP, alpha-fetoprotein. *The longest dimension of the observations was measured on transverse images that provided the best delineation of margins while avoiding the arterial phase.
determined the presence or absence of the following features based on definitions proposed by LI-RADS v2017 (5) : (1) size; (2) arterial phase hyperenhancement (APHE); (3) washout appearance according to type of MRI (conventional washout was defined as hypointensity on the PVP or delayed phase [DP] on ECA-MRI or hypointensity on the PVP on HBA-MRI, modified washout was defined as isointensity with capsule on the PVP and/or DP on ECA-MRI [in other words, illusional washout] or hypointensity on the PVP and/or TP on HBA-MRI); (4) enhancing capsule; (5) ancillary features including a nonenhancing capsule, hypointensity on TP and HBP images, mild to moderate hyperintensity on T2WI, diffusion restriction, mosaic architecture, and intralesional fat; and (6) targetoid appearance. We determined the LI-RADS category of the target observations according to LI-RADS v2017. (5) To assess whether the diagnostic performance of LI-RADS for HCC varies with the application of modified washout on each MRI, we made a modified LI-RADS category that included a modified washout as a major feature, instead of conventional washout. We applied ancillary features to refine the final category, according to LI-RADS v2017. Discordant imaging features and LI-RADS categories between the observers were subsequently resolved by consensus with a third observer (with 20 years of experience in interpreting liver MRI). The threshold growth was excluded from the analysis.
StatiStiCal aNalySiS
Consensus data and per-observer data were used for the comparative statistics. We calculated the sensitivity, specificity, accuracy, positive predictive value, and negative predictive value of LR-5 in the LI-RADS and modified LI-RADS categories for diagnosing HCC, as well as the combination of LR-4 and LR-5 in the LI-RADS category. The McNemar test was used to compare sensitivity, specificity, and accuracy between ECA-MRI and HBA-MRI or between LI-RADS and modified LI-RADS categories.
The kappa test and 95% confidence intervals (CIs) were used to determine the interobserver agreement for major features, ancillary features, and LI-RADS categorization. The results were interpreted as slight agreement for κ values of 0.01-0.20, fair agreement for 0.21-0.40, moderate agreement for 0.41-0.60, substantial agreement for 0.61-0.80, and excellent agreement for 0.81-0.99. P < 0.05 was considered to indicate a significant difference. Calculations were performed with using SAS version 9.4 software (SAS Institute, Inc., Cary, NC) and SPSS, version 20 (IBM, Chicago, IL). Table S3 . HCCs ranged from 8 to 30 mm in diameter (median, 21 mm); 2 (2.1%) HCCs were 8 and 9 mm, 40 (42.1%) were 10-19 mm, and the remaining 53 (55.8%) were ≥20 mm in diameter. On pathology, the capsule and septum were identified in 87 HCCs (91.6%). According to Edmondson's classification, 87 (91.6%) HCCs corresponded to grade 2, seven (7.4%) were grade 3, and the remaining one (1.1%) was grade 1.
Results
CliNiCopatHologiC
CHaRaCteRiStiCS oF patieNtS aND HepatiC oBSeRVatioNS
MRi FeatUReS
Major Features
The major features of 117 observations according to MRI modality are demonstrated in Table 2 and  Supporting Table S4 . APHE was observed in 92 (96.8%) HCCs on ECA-MRI, whereas 83 (87.4%) HCCs were seen on HBA-MRI (Fig. 2) . Conventional washout was observed in 76 (80.0%) HCCs on ECA-MRI and 74 (77.9%) HCCs on HBA-MRI. Twelve (12.6%) showed no conventional washout on both MRIs (Fig. 3) . When applying the modified washout on both MRIs, 11 (11.6%) HCCs on ECA-MRI (Figs. 3 and 4) and 13 (13.7%) HCCs on HBA-MRI (Fig. 3) were considered to show additional washout. An enhancing capsule was observed in 83 (87.4%) HCCs on ECA-MRI (Figs. 2-4 ) and in 45 (47.4%) HCCs on HBA-MRI. APHE and enhancing capsule were more frequently observed on ECA-MRI than on HBA-MRI (Supporting Table S4 ). Nine (9.5%) HCCs showed conventional washout on ECA-MRI but not on HBA-MRI. On the contrary, seven (7.4%) HCCs showed conventional washout on HBA-MRI but not on ECA-MRI (Fig. 4) .
ancillary Features and targetoid appearance
The ancillary features of 117 observations according to MRI modality are demonstrated in Supporting  Table S5 . Most hepatic tumors (91/95, 95.8%) showed hypointensity on T1WI and hyperintensity on T2WI. Most HCCs (91/95, 95.8%) showed diffusion restriction. Intralesional fat was identified in six (6.6%) HCCs. A nonenhancing capsule was observed in 11 (11.6%) HCCs on both MRIs. Mosaic architecture due to intratumoral septa was identified in 40 (42.1%) HCCs on ECA-MRI and 38 (40.0%) HCCs on HBA-MRI. Five (5.2%) HCCs showed iso-or hyperintensity on HBP images on HBA-MRI. One of them showed hypointensity on TP. One ICC showed a targetoid appearance on TP and HBP images that consisted of a central enhancing area with a peripheral hypointense rim, while it was purely hypointense on the PVP and DP on ECA-MRI (Fig. 5) .
li-RaDS CategoRiZatioN
The distribution of LI-RADS criteria for all MRIs is summarized in Table 3 A NET and a sclerosing hemangioma were classified as LR-4 on both MRIs by both observers. In addition, one ICC (25 mm) was categorized as LR-4 (probable HCC without arterial hyperenhancement) with ECA-MRI but as LR-M with HBA-MRI due to its targetoid appearance on TP and HBP images (Fig.  5) . The other ICC (30 mm) was classified as LR-M on both MRIs due to its clear targetoid appearance and gradual contrast-filling feature.
We found two subcentimeter-sized daughter HCCs: one (8 mm) showed APHE but only hypointensity on HBP images without clear conventional washout on both MRIs (LR-3 with ECA-MRI and LR-4 with HBA-MRI), and the other one (9 mm) was identified only on HBP images but was not clearly seen on other sequences including ECA-MRI (LR-1 with ECA-MRI and LR-3 with HBA-MRI). Two DNs were also identified only on HBP images of HBA-MRI but were not clearly seen on ECA-MRI (LR-1 with ECA-MRI and LR-3 with HBA-MRI).
DiagNoStiC peRFoRMaNCe oF li-RaDS CategoRieS FoR HCC DiagNoSiS
The diagnostic accuracy of HCC diagnosis by consensus and per-observer review based on the LI-RADS criteria for each MRI is summarized in Table 3 and  Supporting Table S6 . The diagnostic performance for HCC in both observers was not different from that of consensus data. When analyzing only lesions classified as LR-5 as an HCC diagnosis, the sensitivity (77.9%) and accuracy (82.1%) of ECA-MRI were higher than the sensitivity (66.3%) and accuracy (72.6%) of HBA-MRI (P < 0.001). We achieved 100% specificity for both MRIs with LR-5. When combining LR-4 and On the (A) axial arterial phase, (B) portal venous phase, and (C) delayed phase images after administration of extracellular contrast agent, a 22-mm liver mass (arrows) showed arterial hyperenhancement with no obvious washout. On delayed phase image, the mass showed a peripheral enhancing capsule (black arrows). The tumor was categorized as LR-4 by both observers. After application of illusional washout, the tumor was recategorized as LR-5 by both observers. On MRI after administration of a hepatobiliary agent, the liver mass (arrows) showed arterial hyperenhancement on (D) the arterial phase, isointensity on (E) the portal venous phase, and hypointensity on (F) the transitional phase. The tumor was categorized as LR-4 by both observers. After application of the modified washout, the tumor was recategorized as LR-5 by both observers. On the (A) axial arterial phase, (B) portal venous phase, and (C) delayed phase images after administration of extracellular contrast agent, a 19-mm liver mass (arrows) showed arterial hyperenhancement with no obvious washout. On the delayed phase image, the mass showed a peripheral enhancing capsule (black arrows). The tumor was categorized as LR-4 by observer 1 and LR-5 by observer 2. After application of illusional washout, the tumor was recategorized as LR-5 by both observers. On MRI after administration of a hepatobiliary agent, the liver mass (arrows) showed hyperenhancement on (D) the arterial phase, washout on (E) the portal venous phase, and hypointensity on (F) the transitional phase. The tumor was categorized as LR-5 by both observers. Fig. 5 . ICC in a 43-year-old female. On (A) axial arterial phase, (B) portal venous phase, and (C) delayed phase images after administration of extracellular contrast agent, a 26-mm liver mass (arrows) was seen as a hypovascular tumor, which was assigned as LR-4 by both observers. (D) On axial arterial phase on MRI after administration of a hepatobiliary agent, the liver mass (arrow) showed no arterial hyperenhancement. Targetoid appearance consisting of a central enhancing area with a peripheral hypointense rim was seen (E) on the portal venous phase, (F) transitional phase, and (G) hepatobiliary phase, which indicate cholangiocarcinoma. The tumor was categorized as LR-M by both observers. LR-5 for HCC diagnosis, the sensitivities (97.9% for ECA-MRI and 98.9% for HBA-MRI) and accuracies (95.7% and 97.4%) were significantly increased on both MRIs (P < 0.001), but specificity did not differ significantly (86.4%, P = 0.083 and 90.9%, P = 0.157).
When applying modified LI-RADS, 11 (11.6%) HCCs on ECA-MRI and 13 (13.7%) HCCs on HBA-MRI were recategorized to LR-5, providing higher sensitivities (89.5% for ECA-MRI and 80.0% for HBA-MRI, P < 0.001) and accuracies (91.5%, P = 0.003 and 83.8%, P <0.001), while achieving 100% specificity with both MRIs.
iNteRoBSeRVeR agReeMeNt
Most major features and ancillary features of LI-RADS v2017 showed excellent interobserver agreement (Supporting Table S7 ). Modified washout on ECA-MRI, enhancing capsule on HBA-MRI, and mosaic architecture on both MRIs showed substantial interobserver agreement (κ = 0.742, 0.772, 0.728, and 0.689, respectively). The LI-RADS or modified LI-RADS categories for each MRI showed excellent agreement (0.898, 95% CI, 0.844-0.952, and 0.908, 95% CI, 0.855-0.960) for ECA-MRI; 0.915, 95% CI, 0.871-0.960, and 0.898, 95% CI, 0.848-0.949, for HBA-MRI, respectively; Supporting Table S8 ).
Discussion
Our study demonstrated that in the diagnosis of HCC based on the LI-RADS LR-5 category, ECA-MRI showed better diagnostic performance than HBA-MRI in terms of sensitivity and accuracy, while both examinations achieved 100% specificity. Given that minimizing the false-positive diagnosis of HCC is the main motivation of the AASLD guidelines, the OPTN/UNOS system, and LI-RADS, the peculiar characteristics of HBA-MRI might not fit well with such diagnostic criteria based on the vascular profile of HCC. Thus, when considering the major criteria that we applied, our results are predictable at first glance.
The striking difference in LR-4 categories between the two MRIs was that nine (9.5%) HCCs showed APHE on ECA-MRI but not on HBA-MRI, which might be partly responsible for the lower diagnostic performance of HBA-MRI. (19) This could be explained by the small dosage of HBA-MRI, which is one-fourth that of conventional ECA (0.025 versus 0.1 mmol/kg). (20) The decreased dose in administered volume of HBA can create difficulty in acquiring the optimal late arterial phase that is essential for visualizing HCC. In LI-RADS v2017 as for the nodule detected on antecedent US showing APHE, the preference is given to washout over capsule. (5) Although capsule appearance is less frequently observed on HBA-MRI than ECA-MRI, (21) washout is a concern. There were 19 (20.0%) and 21 (22.1%) HCCs that showed no obvious conventional washout on ECA-MRI and HBA-MRI, respectively, including 12 (12.6%) HCCs with no washout on both MRIs. Among them, nine (9.5%) HCCs showed washout on ECA-MRI but not in the PVP on HBA-MRI. It is well known that washout is more perceptible in the delayed phase than in the PVP. (13, 22) Further, Okamoto et al. showed that certain histologic types of HCC, such as those with better differentiation and trabecular architecture, tend to show continuous enhancement even on the PVP. (23, 24) Early contrast uptake into the hepatocyte even at the PVP might exaggerate PVP washout on HBA-MRI, which may be responsible for the seven (7.4%) HCCs that showed washout only on HBA-MRI. However, with stringent guidelines for PVP washout in HBA-MRI, nonnegligible cases of HCCs could not be categorized into LR-5.
Meanwhile, on ECA-MRI, 11 (11.6%) HCCs were seen as isointense with a capsule on PVP and/or DP, in close agreement with prior reports. (25, 26) Thus, the problem of limited sensitivity while pursuing high specificity with stringent HCC criteria of LI-RADS v2017 (in keeping with the AASLD and EASL) remains unsolved. Sofue et al. emphasized the value of the capsule, which can cause readers to perceive subjective washout derived from an optical illusion by the capsule. (25) Accordingly, when applying an illusional washout in ECA-MRI, 11 (11.6%) HCCs with LR-4 were upgraded to LR-5 while achieving 100% specificity. Although we have achieved substantial interobserver agreement in the grading of illusional washout, we acknowledge the fact that considerable subjectivity still may exist for differentiating true washout from illusional washout. However, if we consider both imaging features to equally represent HCC, such subjectivity will have no significance. Capsule appearance is characteristic of HCC that is a feature rarely encountered in other types of hepatic tumors. (27) (28) (29) (30) To the best of our knowledge, the literature does not describe complete capsule formation in either DN or ICC. As result, we believe that the current HCC imaging diagnosis system (which solely emphasizes the enhancement profile) can improve diagnostic sensitivity by adopting the concept of the tumor capsule. Meanwhile, this is true for 13 (13.7%) HCCs on HBA-MRI when applying washout on TP. There are concerns for applying hypointensity on TP or HBP due to misclassification of small hypervascular ICCs or hemangiomas as HCC (so-called pseudowashout).
In LI-RADS v2017, the imaging criteria for LR-M are redefined by introducing a targetoid mass, which usually refers to ICC or combined HCC-cholangiocarcinoma in the setting of chronic liver disease.
These tumors can be differentiated into LR-M categories before entering the diagnostic table of LI-RADS, using the targetoid appearance. Although caution should be given in using hypointensity on the TP as an alternative to washout appearance, applying ancillary features such as T2 brightness or targetoid appearance makes it possible for most hemangiomas or ICC to be placed in the correct categories.
As an inherent strength of HBA-MRI, one subcentimeter-sized HCC (9 mm) and two DNs (7 and 16 mm) were depicted only on HBP images but were not clearly seen on other sequences or ECA-MRI. There is little evidence regarding the clinical impact of early detection and early treatment for such early HCCs and risky nodules progressing to overt hypervascular HCC in terms of patient outcomes. (31) (32) (33) Given that such risky nodules might not be a "target lesion" for treatment but a "signaling lesion" for second overt hypervascular HCC, early recognition of such nodules will usually lead a clinician to follow up with caution. (34) Another strong point is that one ICC was correctly categorized as LR-M with HBA-MRI due to its targetoid appearance on TP and HBP; it was assigned HCC as LR-4 (hypovascular HCC) on ECA-MRI. Thus, in combining LR-4 and LR-5, HBA-MRI might be better than ECA-MRI at characterization of hepatic tumors due to additional information available on HBP.
This study had several limitations. First, it is a singlecenter prospective study that recruited a cohort of patients with cirrhosis in whom liver nodules 3 cm were detected during US screening. These patients then underwent HBA-MRI, in consideration of its high lesion detectability. In addition, because we conducted this study on patients who had planned surgery, it inevitably introduces selection bias. Accordingly, hepatic tumors in this study may not be representative of clinical practice as our patient cohort is biased toward the large number of HCCs as well as a relatively small number of other malignancy-related or cirrhosis-related benign nodules. However, we were interested not in validation of HCC criteria but in comparing the two MRIs with regard to HCC diagnosis based on LI-RADS.
In conclusion, in the diagnosis of HCC with LI-RADS v2017 ECA-MRI showed better sensitivity and accuracy than HBA-MRI. We achieved better diagnostic performance by applying modified washout on HBA-MRI and ECA-MRI than using the current stringent criteria for washout.
